The advent of BTKi and BCL2 inhibitors for the treatment of CLL have opened the way to new therapeutic avenues and alternative drug combinations to chemotherapy, with the aim of improving safety while ensuring better long-term disease control. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.